Douglas Lane

Aaron Wukmir

Alex Fuhrman

- LifeVantage (LFVN) reported **$229 million in revenue**, a **14% increase**, and **just under $10 million in EBITDA** for the fiscal year ended June 30.  **[0000849146_2192290_0]**  The company aims for a **12% EBITDA model** and maintains a **clean balance sheet** with approximately **$20 million in cash** and **no debt**.  **[0000849146_2192290_2]** 
- The company recently completed the acquisition of **Love Biome**, a gut microbiome-focused company, with the transaction closing on **October 1** and full integration expected by **November 1**.  **[0000849146_2192290_0]**  This acquisition is projected to be **accretive within the first year**.  **[0000849146_2192290_3]** 
- A key product, a natural alternative **GLP-1 product**, launched about a year ago, has shown clinical results of increasing natural GLP-1 production by over **200%** and an average of **one pound per week of weight loss** over twelve weeks with **zero muscle loss**.  **[0000849146_2192290_1]** 
- LifeVantage's business model is characterized by **70% subscription-based revenue**  **[0000849146_2192290_0]** **[0000849146_2192290_1]** **[0000849146_2192290_4]**  and a capital allocation strategy that includes an active **share buyback program** with **$17 million remaining** and an annually increasing dividend.  **[0000849146_2192290_3]**

LifeVantage Discusses Fiscal Year Performance and Strategic Growth

- LifeVantage reported **FY 2025 revenue of $229 million**, a **14% increase**, and **EBITDA just under $10 million**, while maintaining a **strong balance sheet with $20 million in cash and no debt**.  **[0000849146_2192274_1]** **[0000849146_2192274_4]** 
- The company completed the acquisition of **LoveBiome on October 1**, with full integration anticipated by **November 1**, expecting the transaction to be **accretive within the first year**.  **[0000849146_2192274_1]** **[0000849146_2192274_4]** 
- LifeVantage operates with approximately **80% gross margins** and a **70% subscription-based revenue model**, supported by a capital allocation strategy that includes an active **share buyback program ($17 million remaining)** and an **annually increasing dividend**.  **[0000849146_2192274_1]** **[0000849146_2192274_3]** **[0000849146_2192274_4]** **[0000849146_2192274_5]** 
- Growth in FY 2025 was primarily driven by the **U.S. launch of the MindBody GLP-1 System**, with **fiscal 2026 guidance provided** and international growth from this product expected.  **[0000849146_2192274_4]**

LifeVantage Reports FY 2025 Results, Details LoveBiome Acquisition, and Capital Allocation Strategy

- LifeVantage achieved **$229 million in revenue** and **$22 million in EBITDA** for fiscal year 2025, marking **over 14% revenue growth** from FY24, largely due to the MindBody GLP-1 System.  **[849146_2162511_1]** **[849146_2162511_4]**  The company projects **moderate growth** in its core business for FY26.  **[849146_2162511_4]** 
- The company announced the acquisition of **LoveBiome**, a direct selling company specializing in microbiome and gut health, on **September 3rd**, with closing anticipated on **October 1st** and full integration by **November 1st**.  **[849146_2162511_1]** 
- LifeVantage maintains a balanced capital allocation strategy, including a **quarterly dividend** (which has been increased annually for the past three years and included a special dividend in September 2023) and an active **share repurchase program** with **$17 million remaining** under its current authorization.  **[849146_2162511_4]** **[849146_2162511_5]** 
- The MindBody GLP-1 System, a key product, demonstrated an average **11 pounds weight loss** and a **9% decrease in overall body fat** over a 12-week study, notably with **no muscle loss**.  **[849146_2162511_2]**

Lifevantage (LFVN)